Key result
Patient adherence to antihypertensive therapy is achieved by only about half of patients by the end of the first year, contributing significantly to resistant hypertension.
Patient non-adherence is a major contributor to resistant hypertension, with only about half of patients achieving adherence by the end of their first year of treatment.
Answers are grounded in this paper and cite their sources.
Nonadherence drives resistant hypertension; leaves open optimal interventions for prospective trials.
Hypertension is one of the most frequent chronic diseases as well as most important cardiovascular risk factors in developed countries. Blood pressure control to target levels can significantly decrease the risk for development of coronary artery disease, stroke, chronic renal disease and mortality. Adequately maintained blood pressure is very important in high risk patients. In the treatment of hypertension, life style therapy and drug treatment have essential roles. Further, patient adherence plays a significant part of the treatment, too. Importantly, about half of the patients only become adherent to antihypertensive therapy by the end of the first year treatment. Hence, non-adherence of patients is an important cause for resistant hypertension. Adherence is influenced by the complexity of drug regimen and characteristic of drug class, as well as age and gender of patients.
No takes yet. Share an insight, caveat, or question.
Gábor Simonyi (2013) conducted a review in Hypertension. Antihypertensive treatment was evaluated. Patient adherence to antihypertensive therapy is achieved by only about half of patients by the end of the first year, contributing significantly to resistant hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: